Non Invasive Prenatal Testing Market Players:
- Centogene N.V.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CRIFM Prenatal Medical Clinic
- Eurofins LifeCodexx GmbH
- MedGenome Labs Ltd.
- NIPT Hiro Clinic
- FALCO biosystems Ltd.
- Biora Therapeutics,Inc.(Progenity,Inc.)
- F. Hoffmann-La Roche Ltd.
- Illumina Inc.
- Laboratory Corporation of America Holdings.
- Natera Inc.
- Myriad Women’s Health, Inc.
- QIAGEN
- Quest Diagnostics
- CooperSurgical, Inc.
The competitive outlook for the NIPT market is marked by rapid innovation and strategic collaborations aimed at enhancing testing capabilities and market reach. Key players like Natera, Illumina, and Roche are leading the charge, developing advanced technologies that offer greater accuracy and a broader range of genetic screenings.
Companies are now working toward enhancing accessibility for the end user and integrating Non-Invasive Prenatal Testing (NIPT) into routine prenatal care as consumer demand for comprehensive prenatal testing increases in the competitive market. Here is a list of key players operating in the global market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of non invasive prenatal testing is estimated at USD 8.17 billion.
The global non invasive prenatal testing market size crossed USD 7.24 billion in 2025 and is likely to register a CAGR of over 14.3%, exceeding USD 27.56 billion revenue by 2035.
The North America non invasive prenatal testing (NIPT) market will account for 37.30% share by 2035, driven by superior healthcare infrastructure, awareness, and good reimbursement policies.
Key players in the market include Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, and Natera, Inc.
